Mamede de Carvalho

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1223735/publications.pdf

Version: 2024-02-01

375 papers	14,964 citations	34105 52 h-index	26613 107 g-index
387 all docs	387 docs citations	387 times ranked	13323 citing authors

#	Article	IF	Citations
1	Respiratory onset in amyotrophic lateral sclerosis: clinical features and spreading pattern. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 40-44.	1.7	7
2	Percutaneous gastrostomy in amyotrophic lateral sclerosis: a review. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 176-189.	1.7	9
3	Reply to the letter from Gazulla. European Journal of Neurology, 2022, 29, e3-e4.	3.3	0
4	Reinnervation as measured by the motor unit size index is associated with preservation of muscle strength in amyotrophic lateral sclerosis, but not all muscles reinnervate. Muscle and Nerve, 2022, 65, 203-210.	2.2	6
5	Impact of SARS-CoV-2 Infection Among Non-Invasive Ventilated ALS Patients. Journal of Neuromuscular Diseases, 2022, 9, 257-259.	2.6	0
6	Exercise following immobility increases lower motor neuron excitability: F-wave and H-reflex studies. Neurophysiologie Clinique, 2022, , .	2.2	2
7	Respiratory function tests in amyotrophic lateral sclerosis: The role of maximal voluntary ventilation. Journal of the Neurological Sciences, 2022, 434, 120143.	0.6	4
8	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron, 2022, 110, 992-1008.e11.	8.1	51
9	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. Npj Genomic Medicine, 2022, 7, 8.	3.8	23
10	The senile hand: Age effects on intrinsic hand muscle <scp>CMAP</scp> amplitudes influence splitâ€hand index calculations. Muscle and Nerve, 2022, 65, 463-467.	2.2	8
11	Motor neuron disease in three asymptomatic pVal50Met TTR gene carriers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, , 1-3.	1.7	0
12	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
13	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
14	Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 668-678.	1.9	35
15	Influence of age and gender in the sensory nerve fibers excitability. Brain and Behavior, 2022, 12, e2467.	2.2	4
16	Mimicking Amyotrophic Lateral Sclerosis: A Case of a Spinal Dural Arteriovenous Fistula. Case Reports in Neurology, 2022, 13, 802-806.	0.7	0
17	Dynamic Bayesian Networks for stratification of disease progression in Amyotrophic Lateral Sclerosis. European Journal of Neurology, 2022, , .	3.3	5
18	Thyroid dysfunction in Portuguese amyotrophic lateral sclerosis patients. Neurological Sciences, 2022, 43, 5625-5627.	1.9	1

#	Article	IF	Citations
19	Imaging motor unit territory. Clinical Neurophysiology, 2022, , .	1.5	0
20	Mouth occlusion pressure at 100ms (P0.1) as a respiratory biomarker in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 53-60.	1.7	7
21	The cutaneous silent period in motor neuron disease. Clinical Neurophysiology, 2021, 132, 660-665.	1.5	8
22	ALS and fertility: does ALS affect number of children patients have?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 94-100.	1.7	0
23	The Effect of <scp>SMN</scp> Gene Dosage on <scp>ALS</scp> Risk and Disease Severity. Annals of Neurology, 2021, 89, 686-697.	5.3	10
24	Predictive Medicine Using Interpretable Recurrent Neural Networks. Lecture Notes in Computer Science, 2021, , 187-202.	1.3	1
25	Cardiovascular comorbidities in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 421, 117292.	0.6	10
26	Compensatory metabolic and central respiratory drive mechanisms in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 1-3.	1.7	2
27	Phrenic nerve study as outcome in clinical trials for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 9-13.	1.7	3
28	Learning dynamic Bayesian networks from time-dependent and time-independent data: Unraveling disease progression in Amyotrophic Lateral Sclerosis. Journal of Biomedical Informatics, 2021, 117, 103730.	4.3	10
29	Surface electromyography for testing motor dysfunction in amyotrophic lateral sclerosis. Neurophysiologie Clinique, 2021, 51, 454-465.	2.2	4
30	Familial clustering of primary lateral sclerosis and amyotrophic lateral sclerosis: Supplementary evidence for a continuum. European Journal of Neurology, 2021, 28, 2780-2783.	3.3	9
31	Early diagnosis of amyotrophic lateral sclerosis by threshold tracking and conventional transcranial magnetic stimulation. European Journal of Neurology, 2021, 28, 3030-3039.	3.3	19
32	Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1126-1130.	1.9	25
33	Motor neuron disease beginning with frontotemporal dementia: clinical features and progression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 508-516.	1.7	7
34	In the spiral of history: SARS-Cov-2 infection. Clinical Neurophysiology, 2021, 132, 1959-1960.	1.5	0
35	Î³' Fibrinogen as a Predictor of Survival in Amyotrophic Lateral Sclerosis. Frontiers in Cardiovascular Medicine, 2021, 8, 715842.	2.4	1
36	Assessment of sympathetic sudomotor function in amyotrophic lateral sclerosis with electrochemical skin conductance. Clinical Neurophysiology, 2021, 132, 2032-2036.	1.5	6

#	Article	IF	Citations
37	Benign fasciculations: A followâ€up study with electrophysiological studies. Muscle and Nerve, 2021, 64, 670-675.	2.2	3
38	Gold Coast diagnostic criteria increase sensitivity in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2021, 132, 3183-3189.	1.5	22
39	Levosimendan for amyotrophic lateral sclerosis. Lancet Neurology, The, 2021, 20, 775-777.	10.2	0
40	Explainable models of disease progression in ALS: Learning from longitudinal clinical data with recurrent neural networks and deep model explanation. Computer Methods and Programs in Biomedicine Update, 2021, 1, 100018.	3.7	7
41	Electromyographic findings in primary lateral sclerosis during disease progression. Clinical Neurophysiology, 2021, 132, 2996-3001.	1.5	6
42	Modelling Studies of Non-invasive Electric and Magnetic Stimulation of the Spinal Cord. , 2021, , 139-165.		5
43	Delayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal: Where Can We Improve?. Frontiers in Neurology, 2021, 12, 761355.	2.4	12
44	Peripheral neuropathy in ALS: phenotype association. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1133-1134.	1.9	3
45	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
46	Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 89-96.	3.0	4
47	Prognostic value of phrenic nerve conduction study in amyotrophic lateral sclerosis: Systematic review and meta-analysis. Clinical Neurophysiology, 2020, 131, 106-113.	1.5	2
48	Cervical muscle weakness is a marker of respiratory dysfunction in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 323-324.	1.9	3
49	Disease modification in neurodegenerative diseases. Neurology, 2020, 94, 12-13.	1.1	3
50	Prevalence, Incidence, and Clinical-Epidemiological Characterization of Amyotrophic Lateral Sclerosis in Antioquia: Colombia. Neuroepidemiology, 2020, 54, 251-257.	2.3	6
51	Fasciculations: Opening Pandoraâ€™s box. Clinical Neurophysiology, 2020, 131, 239-240.	1.5	0
52	Clinical characteristics in young-adult ALS â€“ results from a Portuguese cohort study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 620-623.	1.7	8
53	Measuring spinal presynaptic inhibition in human subjects. Clinical Neurophysiology, 2020, 131, 1966-1967.	1.5	0
54	Immobility and Fâ€waves: Impact on lower motor neuron excitability. Muscle and Nerve, 2020, 61, 480-484.	2.2	3

#	Article	IF	Citations
55	Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. Cell Reports, 2020, 33, 108456.	6.4	24
56	Modulation of neuromuscular transmission using transcutaneous direct currents: An exploratory study. Neurophysiologie Clinique, 2020, 50, 315-320.	2.2	0
57	Respiratory Neurophysiology in Intensive Care Unit. Journal of Clinical Neurophysiology, 2020, 37, 208-210.	1.7	0
58	Authorsâ€™ reply: Differences between South African and Portuguese ALS cohorts from an environmental perspective. Journal of the Neurological Sciences, 2020, 414, 116932.	0.6	0
59	Needling the future in ALS. Clinical Neurophysiology, 2020, 131, 1973-1974.	1.5	0
60	Motor excitability measurements in early stage familial amyloid polyneuropathy: The influence of tafamidis treatment. Neurophysiologie Clinique, 2020, 50, 145-153.	2.2	1
61	Spreading in ALS: The relative impact of upper and lower motor neuron involvement. Annals of Clinical and Translational Neurology, 2020, 7, 1181-1192.	3.7	34
62	Potential Preventive Strategies for Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2020, 14, 428.	2.8	11
63	Family history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based caseâ€“control study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 671-672.	1.9	3
64	Motor unit estimation by MRI: Integrating old and new ideas. Clinical Neurophysiology, 2020, 131, 1379-1380.	1.5	1
65	Reliability of phrenic nerve conduction study: In healthy controls and in patients with primary lateral sclerosis. Clinical Neurophysiology, 2020, 131, 994-999.	1.5	3
66	VRK1 variants in two Portuguese unrelated patients with childhood-onset motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 291-295.	1.7	7
67	Targeted next-generation sequencing study in familial ALS-FTD Portuguese patients negative for C9orf72 HRE. Journal of Neurology, 2020, 267, 3578-3592.	3.6	2
68	Electrodiagnosis of Amyotrophic Lateral Sclerosis: A Review of Existing Guidelines. Journal of Clinical Neurophysiology, 2020, 37, 294-298.	1.7	14
69	Transforming growth factor-Î² plasma levels and its role in amyotrophic lateral sclerosis. Medical Hypotheses, 2020, 139, 109632.	1.5	9
70	Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 227-234.	1.9	26
71	Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. Journal of Neurology, 2020, 267, 2130-2141.	3.6	23
72	Diaphragmatic CMAP amplitude from phrenic nerve stimulation predicts functional decline in ALS. Journal of Neurology, 2020, 267, 2123-2129.	3.6	5

#	Article	IF	Citations
73	Laryngeal electromyography in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 730-732.	1.9	3
74	AANEM â€“ IFCN glossary of terms in neuromuscular electrodiagnostic medicine and ultrasound. Clinical Neurophysiology, 2020, 131, 1662-1663.	1.5	8
75	A comparative study of South African and Portuguese amyotrophic lateral sclerosis cohorts. Journal of the Neurological Sciences, 2020, 414, 116857.	0.6	12
76	A proposal for new diagnostic criteria for ALS. Clinical Neurophysiology, 2020, 131, 1975-1978.	1.5	268
77	Neurophysiological features of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 11-17.	1.7	11
78	Non-invasive Spinal Cord Stimulation: Relevance of Modelling Studies in Clinical Protocol Design. IFMBE Proceedings, 2020, , 1767-1773.	0.3	0
79	Patient Stratification Using Clinical and Patient Profiles: Targeting Personalized Prognostic Prediction in ALS. Lecture Notes in Computer Science, 2020, , 529-541.	1.3	2
80	Unravelling Disease Presentation Patterns in ALS Using Biclustering for Discriminative Meta-Features Discovery. Lecture Notes in Computer Science, 2020, , 517-528.	1.3	4
81	The â€œsplit-legâ€•syndrome in ALS: specific or variable?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 615-616.	1.7	1
82	A 15-minute session of direct current stimulation does not produce lasting changes in axonal excitability. Neurophysiologie Clinique, 2019, 49, 277-282.	2.2	4
83	Novel TBK1 LoF variant in a family with upper motor neuron predominant motor neuron disease. Journal of the Neurological Sciences, 2019, 403, 117-118.	0.6	5
84	Cervical trans-spinal direct current stimulation: a modelling-experimental approach. Journal of NeuroEngineering and Rehabilitation, 2019, 16, 123.	4.6	14
85	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	7.6	1
86	Testing electrolyte supplementation for muscle cramp. Muscle and Nerve, 2019, 60, 499-500.	2.2	1
87	Interleukin-6 and amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2019, 398, 50-53.	0.6	29
88	Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2019, 56, 5729-5739.	4.0	22
89	Guide the EMG lines. Clinical Neurophysiology, 2019, 130, 1682-1683.	1.5	0
90	The â€˜neurophysiological indexâ€™ predicts survival in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2019, 130, 1684-1685.	1.5	1

#	Article	IF	Citations
91	The split hand in amyotrophic lateral sclerosis: a possible role for the neuromuscular junction. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 368-375.	1.7	16
92	Influence of Environment and Lifestyle on Incidence and Progress of Amyotrophic Lateral Sclerosis in A German ALS Population. , 2019, 10, 205.		18
93	Assessing upper limb function with ALSFRS-R in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 445-448.	1.7	3
94	Distal myopathy and rapidly progressive dementia associated with a novel mutation in the VCP gene: Expanding inclusion body myopathy with early-onset Paget disease and frontotemporal dementia spectrum. Journal of Clinical Neuroscience, 2019, 64, 8-10.	1.5	9
95	Motor unit recruitment in myopathy: The myopathic EMG reconsidered. Journal of Electromyography and Kinesiology, 2019, 45, 41-45.	1.7	2
96	Diaphragmatic Neurophysiology and Respiratory Markers in ALS. Frontiers in Neurology, 2019, 10, 143.	2.4	38
97	Sensory modulation of fasciculation discharge frequency. Muscle and Nerve, 2019, 59, 688-693.	2.2	4
98	Assessment of the reliability of the motor unit size index (MUSIX) in single subject â€œround-robinâ€•and multi-centre settings. Clinical Neurophysiology, 2019, 130, 666-674.	1.5	13
99	SVC Is a Marker of Respiratory Decline Function, Similar to FVC, in Patients With ALS. Frontiers in Neurology, 2019, 10, 109.	2.4	22
100	Electric Field Distribution during Non-Invasive Electric and Magnetic Stimulation of the Cervical Spinal Cord. , 2019, 2019, 5898-5901.		2
101	Modulation of sensory nerve fiber excitability by transcutaneous cathodal direct current stimulation. Neurophysiologie Clinique, 2019, 49, 385-390.	2.2	3
102	Lambertâ€“Eaton Myasthenic Syndrome Plus. Journal of Clinical Neuromuscular Disease, 2019, 21, 119-121.	0.7	0
103	Mitochondrial Neurogastrointestinal Encephalomyopathy: Novel Pathogenic Mutation in Thymidine Phosphorylase Gene in a Patient from Cape Verde Islands. Case Reports in Neurological Medicine, 2019, 2019, 1-4.	0.4	6
104	Muscular cramp: causes and management. European Journal of Neurology, 2019, 26, 214-221.	3.3	27
105	Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity. Clinical Neurophysiology, 2019, 130, 307-314.	1.5	46
106	Non-invasive evaluation of sudomotor function in patients with myasthenia gravis. Neurophysiologie Clinique, 2019, 49, 81-86.	2.2	1
107	C9orf72 expansion is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 118-120.	1.9	14
108	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	7.6	167

#	Article	IF	Citations
109	Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 331-341.	1.7	31
110	Transcutaneous spinal direct current stimulation of the lumbar and sacral spinal cord: a modelling study. Journal of Neural Engineering, 2018, 15, 036008.	3.5	27
111	Diaphragm motor responses to phrenic nerve stimulation in ALS: Surface and needle recordings. Clinical Neurophysiology, 2018, 129, 349-353.	1.5	11
112	Voluntary control of a plegic limb during yawning. Journal of Neurology, 2018, 265, 433-435.	3.6	2
113	Neurophysiologic characterization of periodic paralysis episode in a patient with Andersen-Tawil syndrome. Clinical Neurophysiology, 2018, 129, 558-559.	1.5	0
114	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
115	Beyond fractional anisotropy in amyotrophic lateral sclerosis: the value of mean, axial, and radial diffusivity and its correlation with electrophysiological conductivity changes. Neuroradiology, 2018, 60, 505-515.	2.2	14
116	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
117	Respiratory measures in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 321-330.	1.7	44
118	Plasma level of clubâ€cell (CC â€16) predicts outcome in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2018, 137, 233-237.	2.1	4
119	Cramps and vinpocetine in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 155-156.	1.7	1
120	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.7	22
121	Fasciculation: Does distance really matter?. Clinical Neurophysiology, 2018, 129, 462-463.	1.5	0
122	Very late-onset amyotrophic lateral sclerosis in a Portuguese cohort. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 619-622.	1.7	6
123	Concentric or monopolar electrode for jitter determination in orbicularis oculi. Clinical Neurophysiology, 2018, 129, 2552-2556.	1.5	4
124	Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 506-512.	1.7	7
125	Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology, 2018, 91, e1999-e2009.	1.1	70
126	Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. Lancet Neurology, The, 2018, 17, 842.	10.2	7

#	Article	IF	Citations
127	Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study. Neuroepidemiology, 2018, 51, 177-182.	2.3	45
128	The impact of spasticity on diaphragm contraction: Electrophysiological assessment. Clinical Neurophysiology, 2018, 129, 1544-1550.	1.5	6
129	Sniff nasal inspiratory pressure (SNIP) in amyotrophic lateral sclerosis: Relevance of the methodology for respiratory function evaluation. Clinical Neurology and Neurosurgery, 2018, 171, 42-45.	1.4	11
130	Frequency of C9orf72 hexanucleotide repeat expansion and SOD1Âmutations in Portuguese patients with amyotrophic lateralÂsclerosis. Neurobiology of Aging, 2018, 70, 325.e7-325.e15.	3.1	7
131	Motor unit number estimation (MUNE): Where are we now?. Clinical Neurophysiology, 2018, 129, 1507-1516.	1.5	79
132	The Role of Moderate Aerobic Exercise as Determined by Cardiopulmonary Exercise Testing in ALS. Neurology Research International, 2018, 2018, 1-10.	1.3	29
133	Neuromodulation of lower limb motor responses with transcutaneous lumbar spinal cord direct current stimulation. Clinical Neurophysiology, 2018, 129, 1999-2009.	1.5	12
134	Tele-monitoring of a home-based exercise program in amyotrophic lateral sclerosis: a feasibility study. European Journal of Physical and Rehabilitation Medicine, 2018, 54, 501-503.	2.2	7
135	Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients. European Journal of Neurology, 2018, 25, 1320.	3.3	6
136	Motor Unit Number Index (MUNIX) detects motor neuron loss in pre-symptomatic muscles in Amyotrophic Lateral Sclerosis. Clinical Neurophysiology, 2017, 128, 495-500.	1.5	56
137	The generator site in acquired autoimmune neuromyotonia. Clinical Neurophysiology, 2017, 128, 643-646.	1.5	5
138	Sialorrhoea and reversals in ALS functional rating scale. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 187-188.	1.9	10
139	Added value of electromyography in the diagnosis of myopathy: A consensus exercise. Clinical Neurophysiology, 2017, 128, 697-701.	1.5	12
140	Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 773-779.	1.9	76
141	Brain white matter demyelinating lesions and amyotrophic lateral sclerosis in a patient with C9orf72 hexanucleotide repeat expansion. Multiple Sclerosis and Related Disorders, 2017, 17, 1-4.	2.0	5
142	Young-onset rapidly progressive ALS associated with heterozygous FUS mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 451-453.	1.7	14
143	Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Scientific Reports, 2017, 7, 44709.	3.3	16
144	Seasons and ALS time of death. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 291-295.	1.7	0

#	Article	IF	Citations
145	Correlation between Forced Vital Capacity and Slow Vital Capacity for the assessment of respiratory involvement in Amyotrophic Lateral Sclerosis: a prospective study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 86-91.	1.7	42
146	Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 256-264.	1.7	17
147	Health Status Perspectives in Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2017, 17, 323-329.	1.4	3
148	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
149	Interplay of upper and lower motor neuron degeneration in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2017, 128, 2200-2204.	1.5	4
150	Prolongation of terminal latency of the phrenic nerve in amyotrophic lateral sclerosis â€“ Is it clinically useful, and what are the mechanisms?. Clinical Neurophysiology, 2017, 128, 2094.	1.5	1
151	Riluzole-induced recurrent pancreatitis. Journal of Clinical Neuroscience, 2017, 45, 153-154.	1.5	7
152	International Survey of ALS Experts about Critical Questions for Assessing Patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 505-510.	1.7	17
153	Concentric and monopolar needle for jitter estimation in orbicularis oculi. Journal of the Neurological Sciences, 2017, 381, 1092.	0.6	0
154	Celiac disease and a novel association with a multifocal acquired motor axonopathy (MAMA). Clinical Neurophysiology, 2017, 128, 1596-1598.	1.5	4
155	Risk factors for onset of amyotrophic lateral sclerosis. European Journal of Neurology, 2017, 24, 9-10.	3.3	1
156	Phrenic nerve stimulation is more sensitive than ultrasound measurement of diaphragm thickness in assessing early ALS progression. Neurophysiologie Clinique, 2017, 47, 69-73.	2.2	25
157	Phosphoneurofilament heavy chain and vascular endothelial growth factor as cerebrospinal fluid biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 134-136.	1.7	15
158	Physiology of the fasciculation potentials in amyotrophic lateral sclerosis: which motor units fasciculate?. Journal of Physiological Sciences, 2017, 67, 569-576.	2.1	12
159	Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 528-533.	1.7	30
160	The yin and yang of gastrostomy in the management of ALS. Neurology, 2017, 89, 1435-1436.	1.1	5
161	Modulation of fasciculation frequency in amyotrophic lateral sclerosis: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309686.	1.9	11
162	New insights into the clinical neurophysiological assessment of ALS. Neurophysiologie Clinique, 2016, 46, 157-163.	2.2	6

#	Article	IF	Citations
163	Vestibulo-ocular reflex dynamics withÂhead-impulses discriminates spinocerebellar ataxias types 1, 2 and 3 andÂFriedreich ataxia. Journal of Vestibular Research: Equilibrium and Orientation, 2016, 26, 327-334.	2.0	34
164	Anticompensatory quick eye movements after head impulses: A peripheral vestibular sign in spontaneous nystagmus. Journal of Vestibular Research: Equilibrium and Orientation, 2016, 25, 267-271.	2.0	11
165	Lower motor neuron dysfunction in ALS. Clinical Neurophysiology, 2016, 127, 2670-2681.	1.5	62
166	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.7	84
167	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. Clinical Neurophysiology, 2016, 127, 2684-2691.	1.5	74
168	Epileptic seizures as a presentation of central nervous system involvement in TTR Val30Met-FAP. Journal of Neurology, 2016, 263, 2336-2338.	3.6	8
169	Identification of erythrocyte biomarkers in amyotrophic lateral sclerosis. Clinical Hemorheology and Microcirculation, 2016, 63, 423-437.	1.7	13
170	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
171	Origin of fasciculations in root lesions. Clinical Neurophysiology, 2016, 127, 870-873.	1.5	5
172	Emerging molecular biomarker targets for amyotrophic lateral sclerosis. Clinica Chimica Acta, 2016, 455, 7-14.	1.1	29
173	The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy. Clinical Neurophysiology, 2016, 127, 2222-2227.	1.5	56
174	Fasciculation discharge frequency in amyotrophic lateral sclerosis and related disorders. Clinical Neurophysiology, 2016, 127, 2257-2262.	1.5	32
175	Ultrasound for assessment of diaphragm in ALS. Clinical Neurophysiology, 2016, 127, 892-897.	1.5	76
176	Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2016, 37, 209.e17-209.e21.	3.1	53
177	Markers for upper limb dysfunction in Amyotrophic Lateral Sclerosis using analysis of typing activity. Clinical Neurophysiology, 2016, 127, 925-931.	1.5	12
178	Quality Control of Motor Unit Number Index (MUNIX) Measurements in 6 Muscles in a Single-Subject â€œRound-Robinâ€•Setup. PLoS ONE, 2016, 11, e0153948.	2.5	40
179	Do We Have a Channel Solution for ALS?. EBioMedicine, 2015, 2, 1842-1843.	6.1	1
180	Transthyretin familial amyloid polyneuropathy impact on health-related quality of life. Orphanet Journal of Rare Diseases, 2015, 10, O28.	2.7	5

#	Article	IF	Citations
181	Integrative biomarker discovery in neurodegenerative diseases. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 357-379.	6.6	4
182	Comment on: The Awaji criteria are not always superior to the previous criteria: A metaâ€analysis. Muscle and Nerve, 2015, 52, 467-468.	2.2	1
183	Quality of life in amyotrophic lateral sclerosis patients and caregivers: Impact of assistive communication from early stages. Muscle and Nerve, 2015, 52, 933-941.	2.2	55
184	Prognostic models based on patient snapshots and time windows: Predicting disease progression to assisted ventilation in Amyotrophic Lateral Sclerosis. Journal of Biomedical Informatics, 2015, 58, 133-144.	4.3	27
185	Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis: Another view. Muscle and Nerve, 2015, 51, 460-461.	2.2	1
186	The R of ALSFRS-R: Does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 120-123.	1.7	31
187	Tackling diagnostic delays in ALS. Lancet Neurology, The, 2015, 14, 457-458.	10.2	7
188	Injuries of the Nerves of the Thorax. , 2015, , 525-543.		4
189	Ultrasound in ALS: Is it a sound method?. Clinical Neurophysiology, 2015, 126, 651-652.	1.5	4
190	Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1172-1179.	1.9	97
191	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	14.8	652
192	Axial myoclonus after ischemic stroke. Neurology, 2015, 85, 654-654.	1.1	2
193	Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis. Clinica Chimica Acta, 2015, 438, 342-349.	1.1	25
194	Motoneuron firing in amyotrophic lateral sclerosis (ALS). Frontiers in Human Neuroscience, 2014, 8, 719.	2.0	30
195	Young slow-progressing ALS patients are at higher risk of inappropriate and disease-quickening surgeries. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 621-621.	1.7	0
196	Roles of Vascular Endothelial Growth Factor in Amyotrophic Lateral Sclerosis. BioMed Research International, 2014, 2014, 1-24.	1.9	45
197	Neurophysiological techniques to detect early smallâ€fiber dysfunction in transthyretin amyloid polyneuropathy. Muscle and Nerve, 2014, 49, 181-186.	2.2	30
198	Does surgery accelerate progression of amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 643-646.	1.9	48

#	Article	IF	Citations
199	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions inC9orf72reveals marked differences in results among 14 laboratories. Journal of Medical Genetics, 2014, 51, 419-424.	3.2	118
200	Vascular endothelial growth factor and amyotrophic lateral sclerosis: The interplay with exercise and noninvasive ventilation. Muscle and Nerve, 2014, 49, 545-550.	2.2	12
201	Neurologic complications of craniovertebral dislocation. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 119, 435-448.	1.8	16
202	Delayed diagnosis in ALS: The problem continues. Journal of the Neurological Sciences, 2014, 343, 173-175.	0.6	63
203	Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. Neurodegenerative Disease Management, 2014, 4, 83-102.	2.2	36
204	Motor excitability measurements: The influence of gender, body mass index, age and temperature in healthy controls. Neurophysiologie Clinique, 2014, 44, 213-218.	2.2	9
205	A handful of promises. Clinical Neurophysiology, 2014, 125, 5.	1.5	0
206	Sensitivity of MUP parameters in detecting change in early ALS. Clinical Neurophysiology, 2014, 125, 166-169.	1.5	23
207	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 344-350.	1.7	62
208	Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology, 2014, 125, 2150-2206.	1.5	1,647
209	Split-hand to diagnosis shot. Clinical Neurophysiology, 2013, 124, 219-220.	1.5	0
210	Fasciculation potentials and earliest changes in motor unit physiology in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 963-968.	1.9	93
211	Can inspiratory muscle training increase survival in early-affected amyotrophic lateral sclerosis patients?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 124-126.	1.7	20
212	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	10.2	454
213	Nerve excitabitability and fasciculations. Clinical Neurophysiology, 2013, 124, 1925.	1.5	0
214	Reply. Muscle and Nerve, 2013, 47, 620-621.	2.2	0
215	Dropped head presentation in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 235-235.	1.7	4
216	Orofacial Apraxia in Motor Neuron Disease. Case Reports in Neurology, 2013, 5, 47-51.	0.7	13

#	Article	IF	Citations
217	Primary lateral sclerosis: Predicting functional outcome. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 141-145.	1.7	14
218	No association between VAPB mutations and familial or sporadic ALS in Sweden, Portugal and Iceland. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 620-627.	1.7	11
219	Reduced Myocardial 123-Iodine Metaiodobenzylguanidine Uptake. Circulation: Cardiovascular Imaging, 2013, 6, 627-636.	2.6	78
220	Rapidly progressive frontotemporal dementia and bulbar amyotrophic lateral sclerosis in Portuguese patients with C9orf72 mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 70-72.	1.7	11
221	Origin of Fasciculations in Amyotrophic Lateral Sclerosis and Benign Fasciculation Syndrome. JAMA Neurology, 2013, 70, 1562-5.	9.0	32
222	What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 550-554.	2.1	35
223	Testing upper motor neuron function in amyotrophic lateral sclerosis: the most difficult task of neurophysiology. Brain, 2012, 135, 2581-2582.	7.6	15
224	Economic cost of home-telemonitoring care for BiPAP-assisted ALS individuals. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 533-537.	2.1	37
225	Long-term survival in a patient with amyotrophic lateral sclerosis and respiratory presentation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 396-397.	2.1	0
226	Choreaâ€acanthocytosis presenting as motor neuron disease. Muscle and Nerve, 2012, 45, 293-295.	2.2	11
227	Is it better than it seems or just good enough? The tafamidis saga. Muscle and Nerve, 2012, 46, 14-14.	2.2	7
228	Coexistence of transthyretin familial amyloid polyneuropathy and hereditary neuropathy with liability to pressure palsy. Clinical Neurology and Neurosurgery, 2012, 114, 1355-1357.	1.4	2
229	Associated movement disorders in orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 725-729.	1.9	46
230	Patrikios syndrome in two patients with treatable flail-leg weakness. Journal of Clinical Neuroscience, 2012, 19, 318-321.	1.5	0
231	Prognosis of phrenic nerve injury following thoracic interventions: Four new cases and a review. Clinical Neurology and Neurosurgery, 2012, 114, 199-204.	1.4	22
232	Fasciculation potentials: Still mysterious. Clinical Neurophysiology, 2012, 123, 227-228.	1.5	6
233	Estimating the value of estimation. Clinical Neurophysiology, 2012, 123, 1904-1905.	1.5	0
234	Motor unit firing in amyotrophic lateral sclerosis and other upper and lower motor neurone disorders. Clinical Neurophysiology, 2012, 123, 2312-2318.	1.5	27

#	Article	IF	Citations
235	Decreased heart rate variability predicts death in amyotrophic lateral sclerosis. Muscle and Nerve, 2012, 46, 341-345.	2.2	32
236	Awaji Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Archives of Neurology, 2012, 69, 1410.	4.5	211
237	Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2012, 123, 2454-2459.	1.5	59
238	A 3-month-old baby with H1N1 and Guillain-Barre syndrome. BMJ Case Reports, 2012, 2012, bcr1220115462-bcr1220115462.	0.5	9
239	Respiratory exercise in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 33-43.	2.1	56
240	Does Awaji decrease diagnostic yield in ALS?. Muscle and Nerve, 2012, 46, 142-143.	2.2	2
241	Paralytic shellfish poisoning due to ingestion of Gymnodinium catenatum contaminated cockles â€“ Application of the AOAC HPLC Official Method. Toxicon, 2012, 59, 558-566.	1.6	41
242	EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) â€“ revised report of an EFNS task force. European Journal of Neurology, 2012, 19, 360-375.	3.3	860
243	Exercise and amyotrophic lateral sclerosis. Neurological Sciences, 2012, 33, 9-15.	1.9	58
244	Does the motor cortex influence denervation in ALS? EMG studies of muscles with both contralateral and bilateral corticospinal innervation. Clinical Neurophysiology, 2011, 122, 629-635.	1.5	15
245	Why is ALS so excited?. Clinical Neurophysiology, 2011, 122, 1689-1690.	1.5	4
246	Motor Unit Number Index (MUNIX): A novel neurophysiological marker for neuromuscular disorders; testâ€“retest reliability in healthy volunteers. Clinical Neurophysiology, 2011, 122, 1867-1872.	1.5	106
247	Motor Unit Number Index (MUNIX): Reference values of five different muscles in healthy subjects from a multi-centre study. Clinical Neurophysiology, 2011, 122, 1895-1898.	1.5	43
248	Impact of medical audit on electrodiagnostic medicine in polyneuropathy. Clinical Neurophysiology, 2011, 122, 2523-2529.	1.5	3
249	Fasciculation-cramp syndrome preceding anterior horn cell disease: an intermediate syndrome?. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 459-461.	1.9	19
250	Amyotrophic lateral sclerosis. Current Opinion in Neurology, 2011, 24, 497-503.	3.6	44
251	The Awaji criteria for diagnosis of ALS. Muscle and Nerve, 2011, 44, 456-456.	2.2	22
252	Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Human Molecular Genetics, 2011, 20, 1697-1700.	2.9	127

#	Article	IF	Citations
253	Implementation of an efficient muscle fatigue model in the framework of multibody systems dynamics for analysis of human movements. Proceedings of the Institution of Mechanical Engineers, Part K: Journal of Multi-body Dynamics, 2011, 225, 359-370.	0.8	5
254	Muscle ultrasound detects fasciculations and facilitates diagnosis in ALS. Neurology, 2011, 77, 1508-1509.	1.1	15
255	Lithium treatment in amyotrophic lateral sclerosis: do we have enough trials?. Expert Review of Neurotherapeutics, 2011, 11, 1693-1698.	2.8	3
256	Erythropoietin and amyotrophic lateral sclerosis: Plasma level determination. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 439-443.	2.1	7
257	Finite element studies of the mechanical behaviour of the diaphragm in normal and pathological cases. Computer Methods in Biomechanics and Biomedical Engineering, 2011, 14, 505-513.	1.6	21
258	Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: A sixâ€month longitudinal study. Muscle and Nerve, 2010, 41, 208-211.	2.2	37
259	Acquired amyloid neuropathy in a Portuguese patient after domino liver transplantation. Muscle and Nerve, 2010, 42, 836-838.	2.2	25
260	Symmetry of phrenic nerve motor response in amyotrophic lateral sclerosis. Muscle and Nerve, 2010, 42, 822-824.	2.2	14
261	Home telemonitoring of non-invasive ventilation decreases healthcare utilisation in a prospective controlled trial of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1238-1242.	1.9	123
262	Pseudobulbar syndrome in two patients with human immunodeficiency virus infection. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 220-222.	2.1	5
263	Is a four-hour use of non-invasive ventilation enough to define compliance?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 250-252.	2.1	6
264	The onset of ALS?. Clinical Neurophysiology, 2010, 121, 1709-1710.	1.5	4
265	Lesion of the deep palmar branch of the ulnar nerve: Causes and clinical outcome. Neurophysiologie Clinique, 2010, 40, 159-164.	2.2	17
266	Electrophysiological Studies in Healthy Subjects Involving Caffeine. Journal of Alzheimer's Disease, 2010, 20, S63-S69.	2.6	17
267	Implementation of a Wireless Device for Real-Time Telemedical Assistance of Home-Ventilated Amyotrophic Lateral Sclerosis Patients: A Feasibility Study. Telemedicine Journal and E-Health, 2010, 16, 883-888.	2.8	33
268	A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 456-460.	2.1	101
269	Association of paraspinal and diaphragm denervation in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 63-66.	2.1	43
270	Variation in the neurophysiological examination of amyotrophic lateral sclerosis in Europe. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 443-448.	2.1	5

#	Article	IF	Citations
271	Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis. CNS and Neurological Disorders - Drug Targets, 2010, 9, 764-778.	1.4	34
272	What Is Really New in Progressive Muscle Atrophy?. Archives of Neurology, 2009, 66, 1427.	4.5	16
273	NATURAL HISTORY OF YOUNG-ADULT AMYOTROPHIC LATERAL SCLEROSIS. Neurology, 2009, 73, 648-650.	1.1	0
274	Percutaneous nocturnal oximetry in amyotrophic lateral sclerosis: Periodic desaturation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 154-161.	2.1	41
275	Motor unit changes in thoracic paraspinal muscles in amyotrophic lateral sclerosis. Muscle and Nerve, 2009, 39, 83-86.	2.2	15
276	Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2009, 40, 318-318.	2.2	1
277	A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin. Neuromuscular Disorders, 2009, 19, 66-68.	0.6	5
278	Predicting respiratory insufficiency in amyotrophic lateral sclerosis: The role of phrenic nerve studies. Clinical Neurophysiology, 2009, 120, 941-946.	1.5	72
279	Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis: Longitudinal study. Clinical Neurophysiology, 2009, 120, 2082-2085.	1.5	56
280	An error of self-diagnosis--but what was the real diagnosis?. Practical Neurology, 2009, 9, 284-288.	1.1	1
281	Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 53-57.	2.1	196
282	Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. Journal of Neurology, 2008, 255, 545-550.	3.6	51
283	Myasthenia gravis and respiratory failure related to phrenic nerve lesion. Muscle and Nerve, 2008, 38, 1340-1341.	2.2	5
284	Motor responses of the sternocleidomastoid muscle in patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2008, 38, 1312-1317.	2.2	36
285	Neurophysiological markers in familial amyloid polyneuropathy patients: Early changes. Clinical Neurophysiology, 2008, 119, 1082-1087.	1.5	31
286	A prospective multicentre study on sural nerve action potentials in ALS. Clinical Neurophysiology, 2008, 119, 1106-1110.	1.5	19
287	Paraspinal and limb motor neuron involvement within homologous spinal segments in ALS. Clinical Neurophysiology, 2008, 119, 1607-1613.	1.5	31
288	Accessory nerve stimulation: Motor response of the sternocleidomastoid muscle. Neurophysiologie Clinique, 2008, 38, 133-136.	2.2	6

#	Article	IF	Citations
289	Amyotrophic lateral sclerosis patients and ocular ptosis. Clinical Neurology and Neurosurgery, 2008, 110, 168-170.	1.4	18
290	Electrodiagnostic criteria for diagnosis of ALS. Clinical Neurophysiology, 2008, 119, 497-503.	1.5	927
291	Machado-Joseph disease presenting as motor neuron disease. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 188-191.	2.1	12
292	Abnormal transcranial magnetic stimulation in a patient with presumed psychogenic paralysis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1412-1413.	1.9	9
293	Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 339-349.	2.1	15
294	Youngâ€onset sporadic amyotrophic lateral sclerosis: A distinct nosological entity?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 323-327.	2.1	35
295	Respiratory apraxia in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 180-184.	2.1	12
296	Sleep characteristics of amyotrophic lateral sclerosis in patients with preserved diaphragmatic function. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 101-105.	2.1	75
297	Cerebrotendinous xanthomatosis: No involvement of the autonomic nervous system in a case with severe neuropathy. Neurophysiologie Clinique, 2007, 37, 47-49.	2.2	5
298	Monomelic neurogenic syndromes: A prospective study. Journal of the Neurological Sciences, 2007, 263, 26-34.	0.6	21
299	Clinical patterns in progressive muscular atrophy (PMA): A prospective study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 296-299.	2.1	28
300	Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late- and early-onset cases in Portugal. Muscle and Nerve, 2007, 35, 116-118.	2.2	113
301	Do bulbar-onset amyotrophic lateral sclerosis patients have an earlier respiratory involvement than spinal-onset amyotrophic lateral sclerosis patients?. Europa Medicophysica, 2007, 43, 505-9.	0.5	7
302	Influence of peer review medical audit on pathophysiological interpretation of nerve conduction studies in polyneuropathies. Clinical Neurophysiology, 2006, 117, 979-983.	1.5	9
303	Amplitude, area and duration of the compound muscle action potential change in different ways over the length of the ulnar nerve. Clinical Neurophysiology, 2006, 117, 2085-2092.	1.5	18
304	Does caffeine modify corticomotor excitability?. Neurophysiologie Clinique, 2006, 36, 219-226.	2.2	48
305	Steroid-responsive demyelinating motor neuropathy with conduction block associated with hepatitis C infection and treatment with interferon alpha. Journal of the Peripheral Nervous System, 2006, 11, 353-354.	3.1	6
306	Longstanding right-hand weakness in a patient with myasthenia gravis. Muscle and Nerve, 2006, 34, 670-671.	2.2	1

#	Article	IF	Citations
307	Can Selection of Rapidly Progressing Patients Shorten Clinical Trials in Amyotrophic Lateral Sclerosis?. Archives of Neurology, 2006, 63, 557.	4.5	32
308	Evidence for central abnormality in respiratory control in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 57-60.	2.1	7
309	Ventilation in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 3-4.	2.1	3
310	Upper limb tremor induced by peripheral nerve injury. Neurology, 2006, 67, 1884-1886.	1.1	20
311	Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 746-749.	1.9	121
312	Chronic inflammatory demyelinating polyneuropathy, phrenic nerve and respiratory symptoms. European Journal of Neurology, 2005, 12, 64-66.	3.3	5
313	Quantitating progression in ALS. Neurology, 2005, 64, 1783-1785.	1.1	59
314	The onset of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 388-389.	1.9	17
315	Neurophysiological measures in amyotrophic lateral sclerosis: Markers of progression in clinical trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 17-28.	2.1	71
316	Biochemical characterization of plasma in amyotrophic lateral sclerosis: Amino acid and protein composition. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 104-110.	2.1	6
317	Influence of medical audit on electrodiagnostic evaluation of polyneuropathy. A multicentre study. Clinical Neurophysiology, 2005, 116, 49-55.	1.5	9
318	Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clinical Neurophysiology, 2005, 116, 1571-1580.	1.5	122
319	Pain and calf hypertrophy associated with spontaneous repetitive discharges treated with botulinum toxin. Clinical Neurophysiology, 2005, 116, 2847-2852.	1.5	26
320	Clinical trials in ALS: A review of the role of clinical and neurophysiological measurements. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 202-212.	2.1	37
321	Cramps, muscle pain, and fasciculations. Neurology, 2004, 63, 721-723.	1.1	63
322	Randomised controlled trial in non-invasive ventilation: what trial?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 255-256.	1.2	10
323	Electrodiagnostic assessment of respiratory dysfunction in motor neuron disease. Handbook of Clinical Neurophysiology, 2004, , 513-528.	0.0	7
324	Abrupt onset of progressive muscular atrophy. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 61-62.	1.2	0

#	Article	IF	Citations
325	The Neurophysiological Index in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 108-110.	1.2	54
326	Mutant fibrinogen A-Î±-chain associated with hereditary renal amyloidosis and peripheral neuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11, 200-207.	3.0	20
327	Hereditary sensory neuropathy type 1 in a Portuguese familyâ€"electrodiagnostic and autonomic nervous system studies. Journal of the Neurological Sciences, 2004, 227, 35-38.	0.6	10
328	Repetitive nerve stimulation in myasthenia gravisâ€"relative sensitivity of different muscles. Clinical Neurophysiology, 2004, 115, 2776-2782.	1.5	96
329	Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis. Muscle and Nerve, 2003, 28, 630-633.	2.2	43
330	Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family: Clinical and neurophysiological studies. Muscle and Nerve, 2003, 28, 715-721.	2.2	32
331	Motor-axonal polyneuropathy associated with hepatitis C virus. European Journal of Neurology, 2003, 10, 183-185.	3.3	26
332	Motor responses evoked by transcranial magnetic stimulation and peripheral nerve stimulation in the ulnar innervation in amyotrophic lateral sclerosis: the effect of upper and lower motor neuron lesion. Journal of the Neurological Sciences, 2003, 210, 83-90.	0.6	53
333	Variation in the classification of polyneuropathies among European physicians. Clinical Neurophysiology, 2003, 114, 496-503.	1.5	14
334	Nocturnal pulse oximetry: a new approach to establish the appropriate time for nonâ€invasive ventilation in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 31-35.	1.2	95
335	Clinical and therapeutic implications of presymptomatic gene testing for familial amyloidotic polyneuropathy (FAP). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 26-31.	3.0	8
336	Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 31-35.	1.2	67
337	Increased creatine kinase and spontaneous activity on electromyography, in amyotrophic lateral sclerosis. Electromyography and Clinical Neurophysiology, 2003, 43, 189-92.	0.2	16
338	Compound Muscle Action Potential: Pro. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, S103-S104.	1.2	4
339	Transcranial magnetic stimulation: Summary. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, S117-S118.	1.2	1
340	Progressive bulbospinal amyotrophy in triple A syndrome with AAAS gene mutation. Neurology, 2002, 59, 1823-1823.	1.1	3
341	Clinical and genetic characterization of families with triple A (Allgrove) syndrome. Brain, 2002, 125, 2681-2690.	7.6	137
342	The corticomotor threshold is not dependent on disease duration in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 39-42.	1.2	15

#	Article	IF	Citations
343	Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 126-133.	3.0	59
344	F-Waves and the corticospinal lesion in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 131-136.	1.2	30
345	Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 126-33.	3.0	13
346	Medical technology assessment Electrodiagnosis in motor neuron diseases and amyotrophic lateral sclerosis. Neurophysiologie Clinique, 2001, 31, 341-348.	2.2	9
347	Reproducibility of neurophysiological and myometric measurement in the ulnar nerve-abductor digiti minimi system. Muscle and Nerve, 2001, 24, 1391-1395.	2.2	26
348	Allgrove syndrome in adulthood. Muscle and Nerve, 2001, 24, 292-296.	2.2	37
349	Sympathetic sudomotor function and amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 105-108.	1.2	14
350	Nerve conduction studies in amyotrophic lateral sclerosis. , 2000, 23, 344-352.		136
351	New transthyretin mutation V28M in a Portuguese kindred with amyloid polyneuropathy. Muscle and Nerve, 2000, 23, 1016-1021.	2.2	18
352	Neurophysiological features of fasciculation potentials evoked by transcranial magnetic stimulation in amyotrophic lateral sclerosis. Journal of Neurology, 2000, 247, 189-194.	3.6	31
353	A tentative interpretation of electromyographic regional differences in bulbar- and limb-onset ALS. Neurology, 2000, 54, 536-536.	1.1	1
354	Fibrillation and sharp-waves: Do we need them to diagnose ALS?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, 29-32.	1.2	28
355	Pathophysiological significance of fasciculations in the early diagnosis of ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, S43-S46.	1.2	36
356	Sensory potential can be preserved in severe common peroneal neuropathy. Electromyography and Clinical Neurophysiology, 2000, 40, 61-3.	0.2	5
357	Amyotrophic lateral sclerosis syndrome associated with connective tissue disease; improvement after immunosuppressive therapy. A long-term follow-up case. European Journal of Neurology, 1999, 6, 239-240.	3.3	2
358	Reproducibility of corticomotor threshold: Some observations. , 1999, 22, 538-539.		5
359	Cortical muscle representation in amyotrophic lateral sclerosis patients: Changes with disease evolution. Muscle and Nerve, 1999, 22, 1684-1692.	2.2	33
360	Respiratory disorders in ALS: sleep and exercise studies. Journal of the Neurological Sciences, 1999, 169, 61-68.	0.6	29

#	Article	IF	Citations
361	Can amyotrophic lateral sclerosis patients with respiratory insufficiency exercise?. Journal of the Neurological Sciences, 1999, 169, 69-75.	0.6	88
362	Multifocal motor neuropathy mimicking motor neuron disease: nine cases. Journal of the Neurological Sciences, 1999, 169, 76-79.	0.6	27
363	Reflex sympathetic dystrophy associated with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 1999, 169, 80-83.	0.6	16
364	Variation in diagnostic strategy of the EMG examinationâ€“a multicentre study. Clinical Neurophysiology, 1999, 110, 1814-1824.	1.5	22
365	Fasciculation potentials: A study of amyotrophic lateral sclerosis and other neurogenic disorders. , 1998, 21, 336-344.		90
366	Paralytic shellfish poisoning: clinical and electrophysiological observations. Journal of Neurology, 1998, 245, 551-554.	3.6	51
367	Can medical audit change electromyographic practice?. Electroencephalography and Clinical Neurophysiology - Electromyography and Motor Control, 1998, 109, 496-501.	1.4	9
368	Reflex sympathetic dystrophy precipitated by brachial plexitis. Electromyography and Clinical Neurophysiology, 1998, 38, 459-61.	0.2	1
369	A new method for reproducible coil positioning in transcranial magnetic stimulation mapping. Electroencephalography and Clinical Neurophysiology - Electromyography and Motor Control, 1997, 105, 116-123.	1.4	62
370	Magnetic stimulation in Alzheimer's disease. Journal of Neurology, 1997, 244, 304-307.	3.6	60
371	Motor neuron disease presenting with respiratory failure. Journal of the Neurological Sciences, 1996, 139, 117-122.	0.6	132
372	Cold-induced neuromyotonia. Journal of Neurology, 1996, 243, 614-616.	3.6	4
373	Association of paraspinal and diaphragm denervation in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 0, , 1-4.	2.1	3
374	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4
375	Monitoring disease onset in amyotrophic lateral sclerosis. Nature Reviews Neurology, 0, , .	10.1	0